Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Core One Labs Inc C.COOL

Alternate Symbol(s):  CLABF

Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. Its subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics, which maintain a combined database of more than 275,000 patients.


CSE:COOL - Post by User

Comment by lscfaon Dec 02, 2020 10:31pm
288 Views
Post# 32023886

RE:Listing application for the CSE

RE:Listing application for the CSE
Expected Changes in the Business of the Company

 

Core One is in the process of selling its operations related to the cultivation of cannabis in the United States. The Company also expects to shift production from THC CannaStripsTM at a highly regulated T&T facility to CBD CannaStripsTM at a less regulated facility. The shift from THC CannaStripsTM to CBD CannaStripsTM will also allow the Company to move away from the highly regulated and fractured marijuana market to the less regulated CBD market where the products can be sold via eCommerce to every state in the U.S. and across state lines. The Company also expects to broaden its focus away from cannabinoids and to research the adaptation of its CannaStripsTM to be used with psilocybin. In connection with these expected changes, the Company has begun to acquire Canadian assets (Rejuva and Shahcor) and investigate Canadian acquisition targets in the psilocybin space (Vocan) in order to further advance the Company’s product development efforts.
<< Previous
Bullboard Posts
Next >>